Castle Biosciences Inc. announced the publication of an independent expert consensus paper endorsing its DecisionDx®-Melanoma test as a best-practice tool for managing patients with cutaneous melanoma. The expert panel, consisting of ten melanoma specialists from academic and clinical institutions, reviewed 26 published studies involving more than 7,500 patients. The panel concluded that DecisionDx-Melanoma provides prognostic information independent of traditional clinicopathologic factors and can enhance risk assessment and clinical decision-making when integrated with existing staging systems. The consensus results are already available and were published in the expert panel paper.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598673-en) on December 09, 2025, and is solely responsible for the information contained therein.